Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson-Kissei’s Silodosin For BPH Could Have Oct. 14 User Fee Date

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA accepts Watson-Kissei’s NDA for silodosin to treat benign prostatic hyperplasia.

You may also be interested in...



Phase III Results Buoy Watson’s Benign Prostatic Hyperplasia Candidate

Silodosin would take on GSK’s Avodart and Pfizer’s Cardura XL.

Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?

Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.

King's CorVu Gets Reluctant "No" From Advisory Committee

Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel